SC-19220
CAS No. : 19395-87-0
| Size | Price | Stock |
|---|---|---|
| 5mg | $110 | In-stock |
| 10mg | $200 | In-stock |
| 25mg | $400 | In-stock |
| 50 mg | Get quote | |
| 100 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-102065 |
| M.Wt: | 331.75 |
| Formula: | C16H14ClN3O3 |
| Purity: | >98 % |
| Solubility: | DMSO : 100 mg/mL (ultrasonic) |
SC-19220 is a prostaglandin E2 receptor EP1 antagonist. SC-19220 blocks functional EP1 receptor activation, and RANK/RANKL signaling pathway. SC-19220 inhibits osteoclast formation and bone resorption by pre-existing osteoclasts. SC-19220 can be used for the research of osteoporotic disorders, inflammatory bone resorption[1][2][3].
In Vitro:SC-19220 (3-150 µM; 8 days) dose-dependently inhibits 1,25(OH)2D3- and PGE2 (HY-101952)-induced osteoclast formation and bone resorption in mouse bone marrow cell cultures, with complete inhibition achieved at 75 µM[1].
SC-19220 (75 µM; 4 days) inhibits 1,25(OH)2D3-induced osteoclast formation and bone resorption in mouse bone marrow cell cultures[1].
SC-19220 (75 µM; 1 day) directly inhibits bone resorption by disaggregated Wistar rat osteoclasts without reducing osteoclast number after 1 day of incubation[1].
SC-19220 (30-150 µM; 7 days) does not inhibit granulocyte/macrophage colony formation induced by GM-CSF in mouse bone marrow cell cultures, and slightly enhances colony formation[1].
SC-19220 (75 µM; 8 days) inhibits osteoclast formation and bone resorption induced by IL-11, IL-6, and PTH in mouse osteoblastic cell-bone marrow cell co-cultures after 8 days of incubation[1].
SC-19220 (5-25 μg/mL; 7 days) dose-dependently inhibits PGE2-, 11-deoxy-PGE1 or RANKL/M-CSF-induced osteoclast formation in mouse bone marrow cell cultures, with 25 μg/mL nearly eliminating TRACP+ cell formation[2].
SC-19220 (5-25 μg/mL; 24 h) does not alter PGE2-induced RANKL mRNA expression in primary mouse calvarial osteoblastic cells[2].
SC-19220 (5-25 μg/mL; 1-2 days) dose-dependently reduces RANK and c-Fms mRNA and protein expression in mouse bone marrow macrophages treated with M-CSF and RANKL, with 25 μg/mL causing the greatest reduction[2].
SC-19220 (5-25 μg/mL; 2 days) dose-dependently reduces c-Src protein expression in mouse bone marrow macrophages treated with M-CSF and RANKL[2].
SC-19220 (5-25 μg/mL; 1 day) dose-dependently reduces NFAT2 mRNA and protein expression in mouse bone marrow macrophages treated with M-CSF and RANKL, with 25 μg/mL causing the greatest reduction after 1 day of incubation[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- SC-19220
- Cat. No.:
- HY-102065
- Quantity:
Your information is safe with us.